Review ArticleREVIEWS AND CONTEMPORARY UPDATES
Open Access
Precision Medicine and the Institutional Review Board: Ethics and the Genome
Marc R. Matrana and Bob Campbell
Ochsner Journal March 2020, 20 (1) 98-103; DOI: https://doi.org/10.31486/toj.19.0098
Marc R. Matrana
1Ochsner Cancer Institute, Ochsner Clinic Foundation, New Orleans, LA
2The University of Queensland Faculty of Medicine, Ochsner Clinical School, New Orleans, LA
MD, MS, FACPBob Campbell
3Ochsner Institutional Review Board, Ochsner Clinic Foundation, New Orleans, LA
RPh, BSREFERENCES
- 1.↵
- Avery OT,
- Macleod CM,
- McCarty M
- 2.↵
- Watson JD,
- Crick FH.
- 3.↵The Human Genome Project. National Human Genome Research Institute. www.genome.gov/human-genome-project. Updated October 7, 2019. Accessed February 18, 2020.
- 4.↵
- 5.↵
- 6.↵
- 7.↵
- Gerlinger M,
- Rowan AJ,
- Horswell S,
- et al.
- 8.
- 9.↵
- Kim TM,
- Jung SH,
- An CH,
- et al.
- 10.↵
- 11.↵
- van Kuilenburg AB,
- Haasjes J,
- Richel DJ,
- et al.
- 12.↵
- Abecasis GR,
- Auton A,
- Brooks LD
- 13.↵Lung-MAP: biomarker-targeted second-line therapy in treating patients with recurrent stage IV squamous cell lung cancer [clinical trial]. US National Library of Medicine. clinicaltrials.gov/ct2/show/NCT02154490. Published June 3, 2014. Updated September 9, 2019. Accessed February 18, 2020.
- 14.↵A study to test the effect of the drug larotrectinib in adults and children with NTRK-fusion positive solid tumors (NAVIGATE) [clinical trial]. clinicaltrials.gov/ct2/show/NCT02576431. Published October 15, 2015. Updated February 6, 2020. Accessed February 18, 2020.
- 15.↵Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors, lymphomas, or multiple myeloma (the MATCH screening trial) [clinical trial]. US National Library of Medicine. clinicaltrials.gov/ct2/show/NCT02465060. Published June 8, 2015. Updated February 11, 2020. Accessed February 18, 2020.
- 16.↵
- Amdur R.
- 17.↵
- Amdur R,
- Bankert EA
- 18.↵Novel drug approvals for 2018. US Food and Drug Administration. www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2018. Accessed July 17, 2019.
- 19.↵Novel drug approvals for 2019. US Food and Drug Administration. www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019. Accessed July 26, 2019.
- 20.↵
- Amdur R.
- 21.↵
- 22.↵
- Amdur R,
- Bankert EA.
- 23.↵
In this issue
Precision Medicine and the Institutional Review Board: Ethics and the Genome
Marc R. Matrana, Bob Campbell
Ochsner Journal Mar 2020, 20 (1) 98-103; DOI: 10.31486/toj.19.0098
Jump to section
- Article
- Abstract
- INTRODUCTION
- DEFINITION AND BASIC CONCEPTS OF PRECISION MEDICINE
- GERMLINE TESTING
- NEXT GENERATION SEQUENCING AND BEYOND
- BEYOND GENOMICS
- PHARMACOGENOMICS
- BIOINFORMATICS AND BIG DATA
- PRECISION MEDICINE AND RESEARCH
- INSTITUTIONAL REVIEW BOARDS IN THE ERA OF PRECISION MEDICINE
- CONCLUSION
- ACKNOWLEDGMENTS
- REFERENCES
- References
- Info & Metrics
Cited By...
- No citing articles found.